The Shu complex prevents mutagenesis and cytotoxicity of single-strand specific alkylation lesions

  1. Braulio Bonilla
  2. Alexander I Brown
  3. Sarah R Hengel
  4. Kyle S Rapchak
  5. Debra Mitchell
  6. Catherine A Pressimone
  7. Adeola A Fagunloye
  8. Thong T Luong
  9. Reagan A Russell
  10. Rudri K Vyas
  11. Tony M Mertz
  12. Hani S Zaher
  13. Nima Mosammaparast
  14. Ewa P Malc
  15. Piotr A Mieczkowski
  16. Steven Roberts  Is a corresponding author
  17. Kara A Bernstein  Is a corresponding author
  1. University of Pittsburgh School of Medicine, United States
  2. Washington State University, United States
  3. Washington University in St Louis, United States
  4. University of North Carolina Chapel Hill, United States

Abstract

Three-methyl cytosine (3meC) are toxic DNA lesions, blocking base pairing. Bacteria and humans, express members of the AlkB enzymes family, which directly remove 3meC. However, other organisms, including budding yeast, lack this class of enzymes. It remains an unanswered evolutionary question as to how yeast repairs 3meC, particularly in single-stranded DNA. The yeast Shu complex, a conserved homologous recombination factor, aids in preventing replication-associated mutagenesis from DNA base damaging agents such as methyl methanesulfonate (MMS). We found that MMS-treated Shu complex-deficient cells, exhibit a genome-wide increase in A:T and G:C substitutions mutations. The G:C substitutions displayed transcriptional and replicational asymmetries consistent with mutations resulting from 3meC. Ectopic expression of a human AlkB homolog in Shu-deficient yeast rescues MMS-induced growth defects and increased mutagenesis. Thus, our work identifies a novel homologous recombination-based mechanism mediated by the Shu complex for coping with alkylation adducts.

Data availability

All unique mutations identified by DNA sequencing are reported in Supplemental Table 3 and all sequencing reads are reported in Supplemental Table 5. Raw sequencing reads in fastq format have been submitted to the NCBI short read archive under BioProject accession number PRJNA694993.

The following data sets were generated

Article and author information

Author details

  1. Braulio Bonilla

    Pharmacology and Chemical Biology, University of Pittsburgh School of Medicine, Pittsburgh, United States
    Competing interests
    The authors declare that no competing interests exist.
  2. Alexander I Brown

    Molecular Biosciences, Washington State University, Pullman, United States
    Competing interests
    The authors declare that no competing interests exist.
  3. Sarah R Hengel

    Pharmacology and Chemical Biology, University of Pittsburgh School of Medicine, Pittsburgh, United States
    Competing interests
    The authors declare that no competing interests exist.
  4. Kyle S Rapchak

    Pharmacology and Chemical Biology, University of Pittsburgh School of Medicine, Pittsburgh, United States
    Competing interests
    The authors declare that no competing interests exist.
  5. Debra Mitchell

    Molecular Biosciences, Washington State University, Pullman, United States
    Competing interests
    The authors declare that no competing interests exist.
  6. Catherine A Pressimone

    Pharmacology and Chemical Biology, University of Pittsburgh School of Medicine, Pittsburgh, United States
    Competing interests
    The authors declare that no competing interests exist.
  7. Adeola A Fagunloye

    Pharmacology and Chemical Biology, University of Pittsburgh School of Medicine, Pittsburgh, United States
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-2383-9469
  8. Thong T Luong

    Pharmacology and Chemical Biology, University of Pittsburgh School of Medicine, Pittsburgh, United States
    Competing interests
    The authors declare that no competing interests exist.
  9. Reagan A Russell

    Pharmacology and Chemical Biology, University of Pittsburgh School of Medicine, Pittsburgh, United States
    Competing interests
    The authors declare that no competing interests exist.
  10. Rudri K Vyas

    Molecular Biosciences, Washington State University, Pullman, United States
    Competing interests
    The authors declare that no competing interests exist.
  11. Tony M Mertz

    Molecular Biosciences, Washington State University, Pullman, United States
    Competing interests
    The authors declare that no competing interests exist.
  12. Hani S Zaher

    Biology, Washington University in St Louis, St. Louis, United States
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-7424-3617
  13. Nima Mosammaparast

    Washington University in St Louis, St Louis, United States
    Competing interests
    The authors declare that no competing interests exist.
  14. Ewa P Malc

    Genetics, University of North Carolina Chapel Hill, Chapel Hill, United States
    Competing interests
    The authors declare that no competing interests exist.
  15. Piotr A Mieczkowski

    Genetics, University of North Carolina Chapel Hill, Chapel Hill, United States
    Competing interests
    The authors declare that no competing interests exist.
  16. Steven Roberts

    Molecular Biosciences, Washington State University, Pullman, United States
    For correspondence
    steven.roberts2@wsu.edu
    Competing interests
    The authors declare that no competing interests exist.
  17. Kara A Bernstein

    Pharmacology and Chemical Biology, University of Pittsburgh School of Medicine, Pittsburgh, United States
    For correspondence
    karab@pitt.edu
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-2247-6459

Funding

National Institutes of Health (ES030335)

  • Kara A Bernstein

National Institutes of Health (CA218112)

  • Steven Roberts

American Cancer Society (129182-RSG-16-043-01-DMC)

  • Kara A Bernstein

American Cancer Society (133947-PF-19-132-01-DMC)

  • Sarah R Hengel

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Copyright

© 2021, Bonilla et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Braulio Bonilla
  2. Alexander I Brown
  3. Sarah R Hengel
  4. Kyle S Rapchak
  5. Debra Mitchell
  6. Catherine A Pressimone
  7. Adeola A Fagunloye
  8. Thong T Luong
  9. Reagan A Russell
  10. Rudri K Vyas
  11. Tony M Mertz
  12. Hani S Zaher
  13. Nima Mosammaparast
  14. Ewa P Malc
  15. Piotr A Mieczkowski
  16. Steven Roberts
  17. Kara A Bernstein
(2021)
The Shu complex prevents mutagenesis and cytotoxicity of single-strand specific alkylation lesions
eLife 10:e68080.
https://doi.org/10.7554/eLife.68080

Share this article

https://doi.org/10.7554/eLife.68080

Further reading

    1. Biochemistry and Chemical Biology
    Jianheng Fox Liu, Ben R Hawley ... Samie R Jaffrey
    Tools and Resources

    N 6,2’-O-dimethyladenosine (m6Am) is a modified nucleotide located at the first transcribed position in mRNA and snRNA that is essential for diverse physiological processes. m6Am mapping methods assume each gene uses a single start nucleotide. However, gene transcription usually involves multiple start sites, generating numerous 5’ isoforms. Thus, gene-level annotations cannot capture the diversity of m6Am modification in the transcriptome. Here, we describe CROWN-seq, which simultaneously identifies transcription-start nucleotides and quantifies m6Am stoichiometry for each 5’ isoform that initiates with adenosine. Using CROWN-seq, we map the m6Am landscape in nine human cell lines. Our findings reveal that m6Am is nearly always a high stoichiometry modification, with only a small subset of cellular mRNAs showing lower m6Am stoichiometry. We find that m6Am is associated with increased transcript expression and provide evidence that m6Am may be linked to transcription initiation associated with specific promoter sequences and initiation mechanisms. These data suggest a potential new function for m6Am in influencing transcription.

    1. Biochemistry and Chemical Biology
    2. Microbiology and Infectious Disease
    Eva Herdering, Tristan Reif-Trauttmansdorff ... Ruth Anne Schmitz
    Research Article

    Glutamine synthetases (GS) are central enzymes essential for the nitrogen metabolism across all domains of life. Consequently, they have been extensively studied for more than half a century. Based on the ATP-dependent ammonium assimilation generating glutamine, GS expression and activity are strictly regulated in all organisms. In the methanogenic archaeon Methanosarcina mazei, it has been shown that the metabolite 2-oxoglutarate (2-OG) directly induces the GS activity. Besides, modulation of the activity by interaction with small proteins (GlnK1 and sP26) has been reported. Here, we show that the strong activation of M. mazei GS (GlnA1) by 2-OG is based on the 2-OG dependent dodecamer assembly of GlnA1 by using mass photometry (MP) and single particle cryo-electron microscopy (cryo-EM) analysis of purified strep-tagged GlnA1. The dodecamer assembly from dimers occurred without any detectable intermediate oligomeric state and was not affected in the presence of GlnK1. The 2.39 Å cryo-EM structure of the dodecameric complex in the presence of 12.5 mM 2-OG demonstrated that 2-OG is binding between two monomers. Thereby, 2-OG appears to induce the dodecameric assembly in a cooperative way. Furthermore, the active site is primed by an allosteric interaction cascade caused by 2-OG-binding towards an adaption of an open active state conformation. In the presence of additional glutamine, strong feedback inhibition of GS activity was observed. Since glutamine dependent disassembly of the dodecamer was excluded by MP, feedback inhibition most likely relies on the binding of glutamine to the catalytic site. Based on our findings, we propose that under nitrogen limitation the induction of M. mazei GS into a catalytically active dodecamer is not affected by GlnK1 and crucially depends on the presence of 2-OG.